# Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

> **NCT05112536** · PHASE2 · COMPLETED · sponsor: **G1 Therapeutics, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** Trilaciclib
- **DRUG:** Cylophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin (Investigator discretion)
- **BIOLOGICAL:** Pembrolizumab (Investigator discretion)

## Key facts

- **NCT ID:** NCT05112536
- **Lead sponsor:** G1 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-03
- **Primary completion:** 2022-10-31
- **Final completion:** 2023-03-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05112536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05112536, "Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05112536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*